粒子線治療市場：治療タイプ、コンポーネント、構成、がんタイプ、エンドユーザー別-2025～2030年の世界予測

粒子線治療市場は、2023年に7億7,241万米ドルと評価され、2024年には8億3,150万米ドルに達すると予測され、CAGR 7.94%で成長し、2030年には13億1,887万米ドルに達すると予測されています。

粒子線治療は、主に陽子線治療と重粒子線治療で構成され、がん治療のために荷電粒子を利用する外部ビーム放射線治療の一形態です。周囲の健康な組織へのダメージを最小限に抑えながら腫瘍を標的にする精度の高さから、従来の放射線治療に伴う副作用を軽減し、がん治療における重要な必要性に対応しています。小児がん、前立腺がん、頭頸部がんなど、さまざまながんに応用されており、眼腫瘍や神経疾患の治療にも有用性が高まっています。最終用途の主要セグメントは、専門病院やがん治療センターなどの医療施設です。

市場成長の原動力は、治療提供システムの技術進歩、がん罹患率の増加、先進治療オプションに対する意識の高まり、政府の支援策です。ペンシルビームスキャニングと強度変調陽子線治療における最近の技術革新は治療精度を高め、研究開発に投資する企業に有利な機会をもたらしています。しかし、高い設置コストや運用コスト、限られた施設しか利用できないこと、複雑な規制当局の承認といった課題が、市場拡大の足かせとなっています。さらに、開発途上地域では熟練した専門家の不足が大きな障壁となっています。

成長機会の活用を目指す企業には、費用対効果の高い技術への投資や、新たな治療センターを設立するための医療プロバイダーとの協力関係の構築が推奨されます。さらに、研修プログラムを充実させ、未開拓の新興市場に進出することで、粒子線治療への幅広いアクセスと普及が促進される可能性があります。

粒子線治療市場は、臨床転帰の改善と患者と医療提供者の経済的負担の軽減を中心とした技術革新により、競争が続いています。ハイブリッド治療ソリューションの開発や、個別化された治療計画のためのAIの統合に注力する企業は、産業の最前線にとどまることができます。経済的・物流的な制約があるにもかかわらず、継続的な研究開発努力と先進的ながん治療を支持する規制状況の進化に支えられ、市場の軌道は依然として有望です。このような進歩は、治療のパラダイムを再構築し、粒子線治療アプリケーションの可能性を世界中に拡大することを約束します。

市場力学：急速に進化する粒子線治療市場の主要市場洞察を公開

粒子線治療市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、新たなビジネス機会の獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • がん治療における先進治療の必要性
  • 臨床検査における粒子線治療採用の増加
  • 世界の粒子線治療センターの増加
• 市場抑制要因
  • 粒子線治療機器と手技の高コスト、粒子線治療に対する保険適用の制限
• 市場機会
  • 進行中の陽子線治療研究プログラム
  • 荷電粒子線治療の技術的進歩と個別化がん治療戦略の実現
• 市場課題
  • 粒子線治療放射線被曝に伴うリスク

ポーターのファイブフォース：粒子線治療市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォースフレームワークは、企業の競合を評価し、戦略的機会を探るための明確な手法を記載しています。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これら洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：粒子線治療市場における外部からの影響の把握

外部マクロ環境要因は、粒子線治療市場の業績力学を形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を記載しています。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析：粒子線治療市場における競合情勢の把握

粒子線治療市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、セグメント化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニングマトリックス：粒子線治療市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、粒子線治療市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨：粒子線治療市場における成功への道筋を描く

粒子線治療市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネス機会を活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目セグメントを網羅した市場の包括的な分析を提供しています。

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力を評価します。

2.市場の開拓度：新興市場における成長機会を特定し、既存セグメントにおける拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを記載しています。

3.市場の多様化：最近の製品発売、未開拓の地域、産業の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発とイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています。

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、地域はどこか？

3.市場を形成する主要技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • がん治療における先進的治療法の必要性
    • 臨床検査における粒子線治療の採用増加
    • 世界中で粒子線治療センターが増加
  • 抑制要因
    • 粒子線治療の機器と手順のコストが高く、粒子線治療の保険適用範囲が限られている
  • 機会
    • 進行中の陽子線治療調査プログラム
    • 荷電粒子線治療の技術的進歩と個別化がん治療戦略の実現
  • 課題
    • 粒子線治療放射線被曝に関連するリスク
• 市場セグメンテーション分析
  • 治療タイプ：周囲の組織への損傷リスクが低いため、消費者は陽子線治療を好む
  • コンポーネント：高い精度により、重要臓器の近くの固形腫瘍の治療に製品コンポーネントの利用が増加
  • 構成：多数の患者を同時に治療できるマルチルームシステムの可能性
  • がんタイプ：健康な組織へのリスクが低減したため、頭頸部がんに対する粒子線治療の使用が拡大
  • エンドユーザー：病院や医療機関が高品質のケアを提供することを目指す上で、粒子線治療は重要な役割を果たす
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 法律
  • 環境

第6章 粒子線治療市場：治療タイプ別

• イントロダクション
• 重粒子線治療
• 陽子線治療

第7章 粒子線治療市場：コンポーネント別

• イントロダクション
• 製品
  • サイクロトロン
  • シンクロサイクロトロン
  • シンクロトロン
• サービス

第8章 粒子線治療市場：構成別

• イントロダクション
• マルチルームシステム
• シングルルームシステム

第9章 粒子線治療市場：がんタイプ別

• イントロダクション
• 乳がん
• 頭頸部がん
• 肺がん
• 小児がん
• 前立腺がん

第10章 粒子線治療市場：エンドユーザー別

• イントロダクション
• 外来手術センター
• 病院・クリニック

第11章 南北アメリカの粒子線治療市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第12章 アジア太平洋の粒子線治療市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第13章 欧州・中東・アフリカの粒子線治療市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第14章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
  • IBAとPARTICLEがFLASH陽子線治療調査パートナーシップを開始
  • P-Cureが座位治療用陽子線治療システムのFDA承認を取得し、イスラエルで患者の治療を開始
  • Terapet、次世代がん治療技術のために230万スイスフランを調達
• 戦略分析と提言

企業一覧

• Advanced Oncotherapy plc
• B dot Medical Inc.
• Best Particle Therapy, Inc.
• BioSig Technologies Inc.
• Covenant Health
• Danfysik A/S
• Elekta AB
• Hitachi, Ltd.
• IBA International
• Koninklijke Philips N.V.
• Mevion Medical Systems
• Mitsubishi Electric Corporation
• New Mexico Cancer Center
• Optivus Proton Therapy, Inc.
• P-Cure Ltd
• ProTom International
• Provision Healthcare, LLC
• PTW Freiburg GmbH
• SAH Global LLC
• Shanghai APACTRON Particle Equipment Co., Ltd.
• Siemens Healthineers GmbH
• Stantec Inc.
• Sumitomo Heavy Industries, Ltd.
• Toshiba Medical Systems Corporation
• Xstrahl Ltd.

LIST OF FIGURES

• FIGURE 1. PARTICLE THERAPY MARKET RESEARCH PROCESS
• FIGURE 2. PARTICLE THERAPY MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL PARTICLE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL PARTICLE THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL PARTICLE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL PARTICLE THERAPY MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 15. GLOBAL PARTICLE THERAPY MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. AMERICAS PARTICLE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. AMERICAS PARTICLE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. UNITED STATES PARTICLE THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 19. UNITED STATES PARTICLE THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC PARTICLE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. ASIA-PACIFIC PARTICLE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA PARTICLE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 23. EUROPE, MIDDLE EAST & AFRICA PARTICLE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 24. PARTICLE THERAPY MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 25. PARTICLE THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. PARTICLE THERAPY MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL PARTICLE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL PARTICLE THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL PARTICLE THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. PARTICLE THERAPY MARKET DYNAMICS
• TABLE 7. GLOBAL PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL PARTICLE THERAPY MARKET SIZE, BY HEAVY ION THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL PARTICLE THERAPY MARKET SIZE, BY PROTON THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL PARTICLE THERAPY MARKET SIZE, BY PRODUCT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL PARTICLE THERAPY MARKET SIZE, BY CYCLOTRONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL PARTICLE THERAPY MARKET SIZE, BY SYNCHROCYCLOTRONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL PARTICLE THERAPY MARKET SIZE, BY SYNCHROTRONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL PARTICLE THERAPY MARKET SIZE, BY SERVICE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL PARTICLE THERAPY MARKET SIZE, BY MULTI-ROOM SYSTEM, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL PARTICLE THERAPY MARKET SIZE, BY SINGLE-ROOM SYSTEM, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL PARTICLE THERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL PARTICLE THERAPY MARKET SIZE, BY HEAD & NECK CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL PARTICLE THERAPY MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL PARTICLE THERAPY MARKET SIZE, BY PEDIATRIC CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL PARTICLE THERAPY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL PARTICLE THERAPY MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL PARTICLE THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 31. AMERICAS PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 32. AMERICAS PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
• TABLE 33. AMERICAS PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 34. AMERICAS PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 35. AMERICAS PARTICLE THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 36. ARGENTINA PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 37. ARGENTINA PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 38. ARGENTINA PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 39. ARGENTINA PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
• TABLE 40. ARGENTINA PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 41. ARGENTINA PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 42. BRAZIL PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 43. BRAZIL PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 44. BRAZIL PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 45. BRAZIL PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
• TABLE 46. BRAZIL PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 47. BRAZIL PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 48. CANADA PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 49. CANADA PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 50. CANADA PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 51. CANADA PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
• TABLE 52. CANADA PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 53. CANADA PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 54. MEXICO PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 55. MEXICO PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 56. MEXICO PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 57. MEXICO PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
• TABLE 58. MEXICO PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 59. MEXICO PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 60. UNITED STATES PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 61. UNITED STATES PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 62. UNITED STATES PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 63. UNITED STATES PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
• TABLE 64. UNITED STATES PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 65. UNITED STATES PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 66. UNITED STATES PARTICLE THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 67. ASIA-PACIFIC PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 68. ASIA-PACIFIC PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 69. ASIA-PACIFIC PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 70. ASIA-PACIFIC PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
• TABLE 71. ASIA-PACIFIC PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 72. ASIA-PACIFIC PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 73. ASIA-PACIFIC PARTICLE THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 74. AUSTRALIA PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 75. AUSTRALIA PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 76. AUSTRALIA PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 77. AUSTRALIA PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
• TABLE 78. AUSTRALIA PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 79. AUSTRALIA PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 80. CHINA PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 81. CHINA PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 82. CHINA PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 83. CHINA PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
• TABLE 84. CHINA PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 85. CHINA PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 86. INDIA PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 87. INDIA PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 88. INDIA PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 89. INDIA PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
• TABLE 90. INDIA PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 91. INDIA PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 92. INDONESIA PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 93. INDONESIA PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 94. INDONESIA PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 95. INDONESIA PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
• TABLE 96. INDONESIA PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 97. INDONESIA PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 98. JAPAN PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 99. JAPAN PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 100. JAPAN PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 101. JAPAN PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
• TABLE 102. JAPAN PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 103. JAPAN PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 104. MALAYSIA PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 105. MALAYSIA PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 106. MALAYSIA PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 107. MALAYSIA PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
• TABLE 108. MALAYSIA PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 109. MALAYSIA PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 110. PHILIPPINES PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 111. PHILIPPINES PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 112. PHILIPPINES PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 113. PHILIPPINES PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
• TABLE 114. PHILIPPINES PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 115. PHILIPPINES PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 116. SINGAPORE PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 117. SINGAPORE PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 118. SINGAPORE PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 119. SINGAPORE PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
• TABLE 120. SINGAPORE PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 121. SINGAPORE PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 122. SOUTH KOREA PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 123. SOUTH KOREA PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 124. SOUTH KOREA PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 125. SOUTH KOREA PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
• TABLE 126. SOUTH KOREA PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 127. SOUTH KOREA PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 128. TAIWAN PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 129. TAIWAN PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 130. TAIWAN PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 131. TAIWAN PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
• TABLE 132. TAIWAN PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 133. TAIWAN PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 134. THAILAND PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 135. THAILAND PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 136. THAILAND PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 137. THAILAND PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
• TABLE 138. THAILAND PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 139. THAILAND PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 140. VIETNAM PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 141. VIETNAM PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 142. VIETNAM PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 143. VIETNAM PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
• TABLE 144. VIETNAM PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 145. VIETNAM PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 146. EUROPE, MIDDLE EAST & AFRICA PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 147. EUROPE, MIDDLE EAST & AFRICA PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 148. EUROPE, MIDDLE EAST & AFRICA PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 149. EUROPE, MIDDLE EAST & AFRICA PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
• TABLE 150. EUROPE, MIDDLE EAST & AFRICA PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 151. EUROPE, MIDDLE EAST & AFRICA PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 152. EUROPE, MIDDLE EAST & AFRICA PARTICLE THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 153. DENMARK PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 154. DENMARK PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 155. DENMARK PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 156. DENMARK PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
• TABLE 157. DENMARK PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 158. DENMARK PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 159. EGYPT PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 160. EGYPT PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 161. EGYPT PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 162. EGYPT PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
• TABLE 163. EGYPT PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 164. EGYPT PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 165. FINLAND PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 166. FINLAND PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 167. FINLAND PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 168. FINLAND PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
• TABLE 169. FINLAND PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 170. FINLAND PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 171. FRANCE PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 172. FRANCE PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 173. FRANCE PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 174. FRANCE PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
• TABLE 175. FRANCE PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 176. FRANCE PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 177. GERMANY PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 178. GERMANY PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 179. GERMANY PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 180. GERMANY PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
• TABLE 181. GERMANY PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 182. GERMANY PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 183. ISRAEL PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 184. ISRAEL PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 185. ISRAEL PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 186. ISRAEL PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
• TABLE 187. ISRAEL PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 188. ISRAEL PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 189. ITALY PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 190. ITALY PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 191. ITALY PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 192. ITALY PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
• TABLE 193. ITALY PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 194. ITALY PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 195. NETHERLANDS PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 196. NETHERLANDS PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 197. NETHERLANDS PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 198. NETHERLANDS PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
• TABLE 199. NETHERLANDS PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 200. NETHERLANDS PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 201. NIGERIA PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 202. NIGERIA PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 203. NIGERIA PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 204. NIGERIA PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
• TABLE 205. NIGERIA PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 206. NIGERIA PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 207. NORWAY PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 208. NORWAY PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 209. NORWAY PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 210. NORWAY PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
• TABLE 211. NORWAY PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 212. NORWAY PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 213. POLAND PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 214. POLAND PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 215. POLAND PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 216. POLAND PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
• TABLE 217. POLAND PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 218. POLAND PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 219. QATAR PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 220. QATAR PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 221. QATAR PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 222. QATAR PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
• TABLE 223. QATAR PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 224. QATAR PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 225. RUSSIA PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 226. RUSSIA PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 227. RUSSIA PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 228. RUSSIA PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
• TABLE 229. RUSSIA PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 230. RUSSIA PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 231. SAUDI ARABIA PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 232. SAUDI ARABIA PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 233. SAUDI ARABIA PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 234. SAUDI ARABIA PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
• TABLE 235. SAUDI ARABIA PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 236. SAUDI ARABIA PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 237. SOUTH AFRICA PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 238. SOUTH AFRICA PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 239. SOUTH AFRICA PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 240. SOUTH AFRICA PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
• TABLE 241. SOUTH AFRICA PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 242. SOUTH AFRICA PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 243. SPAIN PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 244. SPAIN PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 245. SPAIN PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 246. SPAIN PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
• TABLE 247. SPAIN PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 248. SPAIN PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 249. SWEDEN PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 250. SWEDEN PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 251. SWEDEN PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 252. SWEDEN PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
• TABLE 253. SWEDEN PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 254. SWEDEN PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 255. SWITZERLAND PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 256. SWITZERLAND PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 257. SWITZERLAND PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 258. SWITZERLAND PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
• TABLE 259. SWITZERLAND PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 260. SWITZERLAND PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 261. TURKEY PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 262. TURKEY PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 263. TURKEY PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 264. TURKEY PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
• TABLE 265. TURKEY PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 266. TURKEY PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 267. UNITED ARAB EMIRATES PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 268. UNITED ARAB EMIRATES PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 269. UNITED ARAB EMIRATES PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 270. UNITED ARAB EMIRATES PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
• TABLE 271. UNITED ARAB EMIRATES PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 272. UNITED ARAB EMIRATES PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 273. UNITED KINGDOM PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 274. UNITED KINGDOM PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 275. UNITED KINGDOM PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 276. UNITED KINGDOM PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
• TABLE 277. UNITED KINGDOM PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 278. UNITED KINGDOM PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 279. PARTICLE THERAPY MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 280. PARTICLE THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

The Particle Therapy Market was valued at USD 772.41 million in 2023, expected to reach USD 831.50 million in 2024, and is projected to grow at a CAGR of 7.94%, to USD 1,318.87 million by 2030.

Particle therapy, primarily comprising proton and heavy ion therapy, is a form of external beam radiotherapy utilizing charged particles for cancer treatment. Due to its precision in targeting tumors while minimizing damage to surrounding healthy tissues, it addresses a critical necessity in cancer treatment, reducing side effects associated with conventional radiation therapy. Applications span a variety of cancers, including pediatric, prostate, and head and neck cancers, with growing utility in treating ocular tumors and neurological disorders. End-use sectors primarily include healthcare facilities like specialized hospitals and cancer treatment centers.

Market growth is driven by technological advancements in treatment delivery systems, increasing incidence of cancer, rising awareness about advanced treatment options, and supportive government initiatives. Recent innovations in pencil beam scanning and intensity-modulated proton therapy have heightened treatment accuracy, presenting lucrative opportunities for companies investing in R&D. However, challenges such as high installation and operational costs, limited availability of facilities, and intricate regulatory approvals constrain market expansion. Additionally, the lack of skilled professionals poses a significant barrier in developing regions.

For businesses aiming to capitalize on growth opportunities, investing in cost-effective technologies and building collaborations with healthcare providers to establish new treatment centers are recommended. Furthermore, enhancing training programs and expanding into untapped emerging markets could foster broader accessibility and adoption of particle therapy.

The particle therapy market remains competitive, with innovation centered on improving clinical outcomes and reducing financial burdens for patients and providers. Companies focusing on developing hybrid therapy solutions and integrating AI for personalized treatment planning can stay at the forefront of the industry. Despite financial and logistical constraints, the market's trajectory remains promising, bolstered by continuous R&D efforts and evolving regulatory landscapes favoring advanced cancer therapies. Such advancements promise to reshape treatment paradigms and expand the potential for particle therapy applications worldwide.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Particle Therapy Market

The Particle Therapy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Need for advanced therapies in cancer treatment
  • Rise in adoption of particle therapy in clinical trials
  • Growing number of particle therapy centers worldwide
• Market Restraints
  • High cost of particle therapy equipment and procedures, along with limited insurance coverage for particle therapy
• Market Opportunities
  • Ongoing proton therapy research programs
  • Technological advances in charged-particle therapy and enabling personalized cancer treatment strategies
• Market Challenges
  • Risk associated with the particle therapy radiation exposure

Porter's Five Forces: A Strategic Tool for Navigating the Particle Therapy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Particle Therapy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Particle Therapy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Particle Therapy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Particle Therapy Market

A detailed market share analysis in the Particle Therapy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Particle Therapy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Particle Therapy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Particle Therapy Market

A strategic analysis of the Particle Therapy Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Particle Therapy Market, highlighting leading vendors and their innovative profiles. These include Advanced Oncotherapy plc, B dot Medical Inc., Best Particle Therapy, Inc., BioSig Technologies Inc., Covenant Health, Danfysik A/S, Elekta AB, Hitachi, Ltd., IBA International, Koninklijke Philips N.V., Mevion Medical Systems, Mitsubishi Electric Corporation, New Mexico Cancer Center, Optivus Proton Therapy, Inc., P-Cure Ltd, ProTom International, Provision Healthcare, LLC, PTW Freiburg GmbH, SAH Global LLC, Shanghai APACTRON Particle Equipment Co., Ltd., Siemens Healthineers GmbH, Stantec Inc., Sumitomo Heavy Industries, Ltd., Toshiba Medical Systems Corporation, and Xstrahl Ltd..

Market Segmentation & Coverage

This research report categorizes the Particle Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Therapy Type, market is studied across Heavy Ion Therapy and Proton Therapy.
• Based on Component, market is studied across Product and Service. The Product is further studied across Cyclotrons, Synchrocyclotrons, and Synchrotrons.
• Based on Configuration, market is studied across Multi-room System and Single-room System.
• Based on Cancer Type, market is studied across Breast Cancer, Head & Neck Cancer, Lung Cancer, Pediatric Cancer, and Prostate Cancer.
• Based on End-User, market is studied across Ambulatory Surgery Centers and Hospitals & Clinics.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Need for advanced therapies in cancer treatment
    • 5.1.1.2. Rise in adoption of particle therapy in clinical trials
    • 5.1.1.3. Growing number of particle therapy centers worldwide
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of particle therapy equipment and procedures, along with limited insurance coverage for particle therapy
  • 5.1.3. Opportunities
    • 5.1.3.1. Ongoing proton therapy research programs
    • 5.1.3.2. Technological advances in charged-particle therapy and enabling personalized cancer treatment strategies
  • 5.1.4. Challenges
    • 5.1.4.1. Risk associated with the particle therapy radiation exposure
• 5.2. Market Segmentation Analysis
  • 5.2.1. Therapy Type: Consumer preference for proton therapy as it provides a reduced risk of damage to surrounding tissues
  • 5.2.2. Component: Rising utilization of product components for treating solid tumors near vital organs due to their high accuracy
  • 5.2.3. Configuration: Potential of a multi-room system for treating a larger number of patients concurrently
  • 5.2.4. Cancer Type: Expanding usage of particle therapy for head & neck cancer owing to reduced risk on healthy tissue
  • 5.2.5. End-User: Significant role of particle therapy in hospitals & clinicals as they strive to provide high-quality care
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Particle Therapy Market, by Therapy Type

• 6.1. Introduction
• 6.2. Heavy Ion Therapy
• 6.3. Proton Therapy

7. Particle Therapy Market, by Component

• 7.1. Introduction
• 7.2. Product
  • 7.2.1. Cyclotrons
  • 7.2.2. Synchrocyclotrons
  • 7.2.3. Synchrotrons
• 7.3. Service

8. Particle Therapy Market, by Configuration

• 8.1. Introduction
• 8.2. Multi-room System
• 8.3. Single-room System

9. Particle Therapy Market, by Cancer Type

• 9.1. Introduction
• 9.2. Breast Cancer
• 9.3. Head & Neck Cancer
• 9.4. Lung Cancer
• 9.5. Pediatric Cancer
• 9.6. Prostate Cancer

10. Particle Therapy Market, by End-User

• 10.1. Introduction
• 10.2. Ambulatory Surgery Centers
• 10.3. Hospitals & Clinics

11. Americas Particle Therapy Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Particle Therapy Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Particle Therapy Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
  • 14.3.1. IBA and PARTICLE Initiate FLASH Proton Therapy Research Partnership
  • 14.3.2. P-Cure Receives FDA Approval For Proton Therapy System For Treatment in Seated Position and Will Begin Treating Patients In Israel
  • 14.3.3. Terapet raises CHF 2.3 million for its next-generation cancer treatment technology
• 14.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Advanced Oncotherapy plc
• 2. B dot Medical Inc.
• 3. Best Particle Therapy, Inc.
• 4. BioSig Technologies Inc.
• 5. Covenant Health
• 6. Danfysik A/S
• 7. Elekta AB
• 8. Hitachi, Ltd.
• 9. IBA International
• 10. Koninklijke Philips N.V.
• 11. Mevion Medical Systems
• 12. Mitsubishi Electric Corporation
• 13. New Mexico Cancer Center
• 14. Optivus Proton Therapy, Inc.
• 15. P-Cure Ltd
• 16. ProTom International
• 17. Provision Healthcare, LLC
• 18. PTW Freiburg GmbH
• 19. SAH Global LLC
• 20. Shanghai APACTRON Particle Equipment Co., Ltd.
• 21. Siemens Healthineers GmbH
• 22. Stantec Inc.
• 23. Sumitomo Heavy Industries, Ltd.
• 24. Toshiba Medical Systems Corporation
• 25. Xstrahl Ltd.